Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Cheng, Xiao Bo ^a,b   Sato, Norihiro ^a   Kohi, Shiro ^a   Yamaguchi, Koji ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HAS2 PROTEIN; HYAL1 PROTEIN; HYALURONIC ACID; HYALURONIDASE; SYNTHETASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TISSUE LEVEL; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYALURONIC ACID; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84892763014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080765     Document Type: Article

References (31)

1. Jimeno A, Hidalgo M (2006) Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 5(4): 787-796. doi: 10.1158/1535-7163.MCT-06-0005. PubMed: 16648548.
2. Ansari D, Rosendahl A, Elebro J, Andersson R (2011) Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 98(8): 1041-1055. doi:10.1002/bjs.7574. PubMed: 21644238.
3. Jamieson NB, Carter CR, McKay CJ, Oien KA (2011) Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 17(10): 3316-3331. doi:10.1158/1078-0432.CCR-10- 3284. PubMed: 21444679.
4. Winter JM, Yeo CJ, Brody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107(1): 15-22. doi:10.1002/jso.23192. PubMed: 22729569.
5. Turley EA, Noble PW, Bourguignon LY (2002) Signaling properties of hyaluronan receptors. J Biol Chem 277(7): 4589-4592. doi:10.1074/jbc.R100038200. PubMed: 11717317.
6. Itano N, Kimata K (2002) Mammalian hyaluronan synthases. IUBMB Life 54(4): 195-199. doi:10.1080/15216540214929. PubMed: 12512858.
7. Stern R (2004) Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 83(7): 317-325. doi:10.1078/0171-9335-00392. PubMed: 15503855.
8. Itano N, Zhuo L, Kimata K (2008) Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 99(9): 1720-1725. doi:10.1111/j.1349-7006.2008.00885.x. PubMed: 18564137.
9. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M et al. (2011) Hyaluronan in human malignancies. Exp Cell Res 317(4): 383-391. doi: 10.1016/j.yexcr.2010.11.017. PubMed: 21134368.
10. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R et al. (1998) Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58(2): 342-347. PubMed: 9443415.
11. Setälä LP, Tammi MI, Tammi RH, Eskelinen MJ, Lipponen PK et al. (1997) Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 79(7-8): 1133-1138. PubMed: 10098747.
12. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U et al. (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156(2): 529-536. doi:10.1016/S0002-9440(10)64757-8. PubMed: 10666382.
13. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U et al. (2001) High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 37(7): 849-856. doi: 10.1016/S0959-8049(00) 00448-2. PubMed: 11313172.
14. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F et al. (2003) Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 63(10): 2638-2644. PubMed: 12750291.
15. Kramer MW, Golshani R, Merseburger AS, Knapp J, Garcia A et al. (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57(1): 86-93. doi:10.1016/j.eururo.2009.03.057. PubMed: 19345473.
16. Kramer MW, Escudero DO, Lokeshwar SD, Golshani R, Ekwenna OO et al. (2011) Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 117(6): 1197-1209. doi:10.1002/cncr.25565. PubMed: 20960509.
17. Mahlbacher V, Sewing A, Elsässer HP, Kern HF (1992) Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. Eur J Cell Biol 58(1): 28-34. PubMed: 1644063.
18. Fries H, Elsässer HP, Mahlbacher V, Neumann K, Kern HF (1994) Localisation of hyaluronate (HA) in primary tumors and nude mouse xenografts of human pancreatic carcinomas using a biotinylated HAbinding protein. Virchows Arch 424(1): 7-12. PubMed: 7526947.
19. Abetamann V, Kern HF, Elsässer HP (1996) Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res 2(9): 1607-1618. PubMed: 9816340.
20. Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA (2000) Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 1502(2): 201-206. doi: 10.1016/S0925-4439(00)00051-X. PubMed: 11040445.
21. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N et al. (2012) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62(1): 112-120. PubMed: 22466618.
22. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3): 418-429. doi:10.1016/j.ccr.2012.01.007. PubMed: 22439937.
23. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J (2010) Tumor microenvironment and progression of pancreatic cancer. Exp Oncol 32(3): 128-131. PubMed: 21403605.
24. Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH et al. (2009) Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer 9: 143. doi: 10.1186/1471-2407-9-143. PubMed: 19435493.
25. Sato N, Maehara N, Goggins M (2004) Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64(19): 6950-6956. doi: 10.1158/0008-5472.CAN-04-0677. PubMed: 15466186.
26. Csoka AB, Frost GI, Stern R (2001) The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 20(8): 499-508. doi: 10.1016/S0945-053X(01)00172-X. PubMed: 11731267.
27. Csóka AB, Frost GI, Heng HH, Scherer SW, Mohapatra G et al. (1998) The hyaluronidase gene HYAL1 maps to chromosome 3p21.2-p21.3 in human and 9F1-F2 in mouse, a conserved candidate tumor suppressor locus. Genomics 48(1): 63-70. doi:10.1006/geno.1997.5158. PubMed: 9503017.
28. Frost GI, Mohapatra G, Wong TM, Csóka AB, Gray JW et al. (2000) HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene 19(7): 870-877. doi:10.1038/sj.onc.1203317. PubMed: 10702795.
29. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD et al. (2001) Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 276(15): 11922-11932. doi:10.1074/jbc.M008432200. PubMed: 11278412.
30. Tan JX, Wang XY, Li HY, Su XL, Wang L et al. (2011) HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Int J Cancer 128(6): 1303-1315. doi:10.1002/ijc.25460. PubMed: 20473947.
31. Neesse A, Michl P, Frese KK, Feig C, Cook N et al. (2011) Stromal biology and therapy in pancreatic cancer. Gut 60(6): 861-868. doi: 10.1136/gut.2010. 226092. PubMed: 20966025.